English | Español

Technology/Innovation
+ Technology/Innovation
Patient Daily Report | May 5, 2023

Eli Lilly on new Alzheimer's drug: 'We are extremely pleased that donanemab yielded positive clinical results'
+ Technology/Innovation
Patient Daily | May 4, 2023

Device Talks Boston 2023
+ Community
Patient Daily | May 4, 2023

Patagonia Health Certified as an NC Minority-Owned Business
+ Community
Patient Daily | May 4, 2023

RELIAS HONORED AS STEVIE AWARD WINNER FOR CUSTOMER SERVICE DEPARTMENT OF THE YEAR IN 2023 AMERICAN BUSINESS AWARDS
+ Technology/Innovation
Patient Daily | May 4, 2023

RELIAS ANNOUNCES UPDATES TO LEARNER MOBILE APP
+ Community
Patient Daily | May 4, 2023

NURSE.COM CELEBRATES NURSES DURING NATIONAL NURSES WEEK
+ Community
Patient Daily | May 4, 2023

Xoran Technologies® Announces New Independent Director
+ Technology/Innovation
Patient Daily | May 4, 2023

Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients

Trending
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Regulatory
M. Y. Bailey | Aug 7, 2026

PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports | Aug 10, 2026

SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation